IGF-1 LR3
A long-acting analog of insulin-like growth factor 1; not FDA-approved.
What it is
IGF-1 LR3 is a lab-modified version of insulin-like growth factor 1, engineered to evade the binding proteins that normally restrain IGF-1 — making it substantially more potent in cell and animal experiments. It exists for laboratory research and was never developed as a human drug.
Its bodybuilding reputation rests on IGF-1's central role in growth signaling. The same biology is why the theoretical risk profile is serious: IGF-1 signaling is deeply entangled with cell proliferation, hypoglycemia is a known acute concern, and no human safety program has ever been run.
What researchers have actually studied it for
Cell growth and muscle physiology in laboratory and animal research; designed as a research reagent, never developed for humans.
How it works
Native IGF-1 with an arginine substitution and a 13-amino-acid extension that together wreck its binding-protein affinity — so instead of circulating 98% sequestered, it stays free and active. In the lab that means prolonged, amplified IGF-1 receptor signaling: growth, glucose uptake, proliferation.
The molecule itself
Human IGF-1 (70 residues) with an arginine-for-glutamate swap at position 3 and a 13-residue N-terminal extension — modifications that wreck binding-protein affinity, leaving the molecule free and persistently active. Designed explicitly as a cell-culture reagent where that freedom is the point.
Where it came from
Created in the 1990s as a cell-culture reagent — media suppliers needed IGF-1 that binding proteins wouldn't soak up. Native IGF-1 (mecasermin) did become a niche approved drug for severe IGF-1 deficiency; the LR3 lab variant never entered human development but escaped into physique-culture folklore.
The timeline
1980s
IGF-1 biology and binding-protein system mapped.
1990s
LR3 engineered for culture media; becomes a biotech workhorse.
2005
Native IGF-1 (mecasermin) approved for severe deficiency — the legitimate cousin.
2000s+
Physique-culture adoption of the lab reagent; anti-doping prohibition.
What the research record actually contains
- Extensive laboratory use as a cell-growth reagent — its actual purpose.
- Animal growth studies.
- Zero human trials of any kind; the approved cousin mecasermin's clinical file (hypoglycemia warnings included) is the nearest human signal.
What could change this assessment
None as a human product, ever — its purpose is laboratory. The legitimate IGF-1 axis story continues in rare-disease medicine and, cautionarily, in oncology research about the axis's role in cancer growth.
What's known about risks
Acutely, IGF-1 signaling drives glucose down — mecasermin's label carries serious hypoglycemia warnings, and LR3's binding-protein escape plausibly sharpens that. Chronically, unrestrained proliferative signaling is the theoretical cancer-risk conversation nobody has data to close. No human file exists.
Where it stands legally
A research reagent, never approved for human use anywhere; prohibited in tested sport as an IGF-1 analog.
Worth asking a licensed provider
- 1.Do I understand this is a cell-culture reagent with zero human trials?
- 2.If muscle growth is the goal, what does my training, protein intake and recovery picture look like first?
- 3.Am I subject to any testing regime where IGF-1 analogs end careers?
Common claims, corrected
“It's just stronger IGF-1.”
Reality: It's IGF-1 with its safety leash removed — binding proteins are the body's control system, and evading them was a design goal for dishes, not people.
“Localized injection grows local muscle.”
Reality: Site-growth lore has no human data, and IGF-1's systemic effects (glucose above all) don't respect injection geography.
IGF-1 LR3 FAQ
Is IGF-1 LR3 safe for humans?
Unknown in the strictest sense — no human trials exist. The known biology raises non-trivial concerns: acute hypoglycemia and the long-term implications of amplified growth signaling.
Is IGF-1 LR3 banned in sports?
Yes — IGF-1 and its analogs are prohibited in tested sport.
Does IGF-1 LR3 build muscle?
It drives growth signaling in muscle cells in the lab. Whether gray-market use in humans builds meaningful muscle, and at what cost, has never been studied — the risk side of that equation is the loud part.
What do binding proteins normally do for IGF-1?
They sequester ~98% of it, buffering delivery and duration — the regulatory system LR3 was built to evade. In a dish that's convenience; in a body it's the safety architecture.
What does the approved IGF-1 drug's label say?
Mecasermin carries serious hypoglycemia warnings and rare-disease-only indications — the closest human file to LR3, and a sobering proxy for its acute risks.